Findings

What do systematic reviews say?

31 questions · 34 findings · 3 reviews · Hepato-Biliary

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 8.8%GRADE not reported 0 · 0%Very low 23 · 67.6%Low 4 · 11.8%Moderate 4 · 11.8%High 0 · 0%

Phamacotherapies that specifically target ammonia vs placebo or non‐absorbable disaccharides

Blood ammonia concentrations (µmol/L*week) · adults with cirrhosis and hepatic encephalopathy

2 findings from 1 review

Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in… 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 90 participants
Very low
Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in… 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 178 participants
Very low

Phamacotherapies that specifically target ammonia vs placebo or non‐absorbable disaccharides

Hepatic encephalopathy · adults with cirrhosis and hepatic encephalopathy

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in… 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Phamacotherapies that specifically target ammonia vs placebo or non‐absorbable disaccharides

Serious adverse events · adults with cirrhosis and hepatic encephalopathy

1 finding from 1 review

Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in… 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
Very low

Phamacotherapies that specifically target ammonia vs placebo or non‐absorbable disaccharides

Non‐serious adverse events · adults with cirrhosis and hepatic encephalopathy

1 finding from 1 review

Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in… 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
Very low

Phamacotherapies that specifically target ammonia vs placebo or non‐absorbable disaccharides

Health‐related quality of life · adults with cirrhosis and hepatic encephalopathy

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in… 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Phamacotherapies that specifically target ammonia vs placebo or non‐absorbable disaccharides

Plasma ammonia concentration (µmol/L) · adults with cirrhosis and hepatic encephalopathy

1 finding from 1 review

Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in… 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 85 participants
Very low

Lactulose vs lactitol

Non‐serious adverse events (secondary outcome) · prevention and treatment of hepatic encephalopathy in people with cirrhosis

It is very uncertain whether lactulose changes non‐serious adverse events (secondary outcome) compared with lactitol (very low certainty).

1 finding from 1 review

Non‐absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and… 2016 · Cochrane Headline outcomes only
RR 1.55 [0.88, 2.74]
6 studies · 169 participants
Very low

Lactulose vs lactitol

All‐cause mortality · prevention and treatment of hepatic encephalopathy in people with cirrhosis

It is very uncertain whether lactulose changes mortality compared with lactitol (very low certainty).

1 finding from 1 review

Non‐absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and… 2016 · Cochrane Headline outcomes only
RR 1.3 [0.59, 2.85]
8 studies · 225 participants
Very low

Lactulose vs lactitol

Hepatic encephalopathy · prevention and treatment of hepatic encephalopathy in people with cirrhosis

It is very uncertain whether lactulose changes hepatic encephalopathy compared with lactitol (very low certainty).

1 finding from 1 review

Non‐absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and… 2016 · Cochrane Headline outcomes only
RR 1 [0.84, 1.19]
7 studies · 194 participants
Very low

Lactulose vs lactitol

Serious adverse events · prevention and treatment of hepatic encephalopathy in people with cirrhosis

It is very uncertain whether lactulose changes serious adverse events compared with lactitol (very low certainty).

1 finding from 1 review

Non‐absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and… 2016 · Cochrane Headline outcomes only
RR 1.56 [0.84, 2.88]
9 studies · 245 participants
Very low

Lactulose vs lactitol

Secondary outcome: quality of life · prevention and treatment of hepatic encephalopathy in people with cirrhosis

The review found no eligible studies for this question.

1 finding from 1 review

Non‐absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found